This association of HDAC6 with amyloid pathology may indicate that the use of agents targeting this enzyme may lead to a more effective reduction of β-amyloid plaques and soluble toxic Aβ-oligomers in the brain of patients with Alzheimer’s disease. This evidence concerns the gene HDAC6 and early-onset autosomal dominant Alzheimer disease.